Signal Transduction and Targeted Therapy (Feb 2023)
Discovery of C19-9 as a novel non-RGD inhibitor of αvβ3 to overcome enzalutamide resistance in castration-resistant prostate cancer
Abstract
No abstracts available.
Signal Transduction and Targeted Therapy (Feb 2023)